Tobrex
(Tobramycin)ApprovedSmall molecule
Tobramycin is an antibiotic used to treat serious bacterial infections, including infections of the lungs (especially in cystic fibrosis patients), eyes, and other parts of the body caused by susceptible bacteria.[2] Tobrex is currently approved and in use across 20 indications[4].[1]
Tobrex is one of 334 small molecule programs targeting Sinusitis. It is currently in Approved.
20
Indications
33
Total Trials
0
Active Trials
333
Competitors
9
FDA Applications
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Tobrex
VViatris Specialty LLC
Approved
Jakafi
IncytePreclinical
Innohep
Jazz PharmaceuticalsPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Prevacid
TakedaPreclinical
Acanya
PfizerPreclinical
Primaquine
SanofiPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Zantac 150
CChattem
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cystic Fibrosis9 trials
Show 6 more trials
Open Fracture2 trials
Bacterial Conjunctivitis2 trials
Bronchiectasis2 trials
14 more indications
Glaucoma1 trial
Prospective1 trial
Surgical Site Infection1 trial
Efficacy1 trial
Conjunctivitis1 trial
MPA1 trial
Wound Infection1 trial
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
TOBREX
NDA NDA050541
Jan 1, 1982
TOBREX
NDA NDA050555
Jan 1, 1982
NEBCIN
NDA NDA050477
Jan 1, 1982
NEBCIN
NDA NDA050519
Dec 22, 1997
TOBI
NDA NDA050753
Jul 13, 2004
TOBRAMYCIN SULFATE
NDA NDA050789
Oct 12, 2012
BETHKIS
NDA NDA201820
Mar 22, 2013
TOBI PODHALER
NDA NDA201688
Dec 2, 2014
KITABIS PAK
NDA NDA205433
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Tobrex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tobramycin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Tobrex. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 70s Ribosome Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- VViatris Specialty LLC